Outcomes by DLL3 expression status with first-line (1L) obrixtamig plus chemotherapy and atezolizumab in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Subgroup analysis of the ongoing Phase Ia/b DAREON®-8 study (ESMO Asia 2026) - Oct 1, 2026 - Abstract #965P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3
|
|
Solange Peters; Rafal Dziadziuszko; Ewa Kalinka; Anas Gazzah; Sophie Cousin; Maria Eugenia Olmedo Garcia; David Vicente Baz; Tirrell Johnson; Tatsuya Yoshida; Manuel Domine; Noriko Yanagitani; Naoki Inui; Hiroshi Kagamu; Yiyuan Ma; Nicolas Dorleacq; Dian Yang; Valeria Lifke; Ticiana A. Leal
|